Related Experiment Video

Updated: Jun 17, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.2K

IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients

Maryam Karamikheirabad1, Junyue Zhang1, Ae-Ri Ahn1

  • 1Department of Pathology, Medical School, Jeonbuk National University, Jeonju 54896, Republic of Korea.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed
Abstract

Insights

Interleukin 13 receptor alpha 2 (IL-13Rα2) expression predicts poorer outcomes in osteosarcoma. Targeting IL-13Rα2 may improve chemotherapy response and offer a new therapeutic strategy for this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Interleukin 13 receptor alpha 2 (IL-13Rα2) is implicated in human cancer progression.
  • Limited research exists on IL-13Rα2's role in osteosarcoma.

Purpose of the Study:

  • To investigate the expression and functional roles of IL-13Rα2 in osteosarcoma progression.

Main Methods:

  • Evaluated IL-13Rα2 expression in 37 human osteosarcoma tissues and cell lines.
  • Assessed the impact of IL-13Rα2 overexpression and knockdown on cell proliferation, migration, invasion, and apoptosis.
  • Analyzed molecular changes including TGF-β, snail, cyclin D1, BCL2, and BAX expression.
  • Investigated IL-13Rα2's effect on doxorubicin sensitivity in vitro and in vivo.

Main Results:

  • IL-13Rα2 positivity correlated with shorter overall and relapse-free survival in osteosarcoma patients.
  • Overexpression of IL-13Rα2 enhanced osteosarcoma cell proliferation, migration, and invasion, while knockdown reduced these effects.
  • IL-13Rα2 modulated key proteins involved in cell growth and apoptosis, and influenced doxorubicin resistance.

Conclusions:

  • IL-13Rα2 expression serves as a potential prognostic biomarker for osteosarcoma.
  • IL-13Rα2 impacts osteosarcoma cell behavior and resistance to doxorubicin.
  • Targeting IL-13Rα2 presents a promising therapeutic strategy for osteosarcoma.
Keywords:
IL-13Rα2doxorubicinosteosarcomaprognosis

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...